클로바잠 (Korean Wikipedia)
Analysis of information sources in references of the Wikipedia article "클로바잠" in Korean language version.
refsWebsite
Global rank
Korean rank
11th place
310th place
1st place
1st place
3,823rd place
2,321st place
low place
low place
low place
low place
low place
low place
low place
low place
4,334th place
1,223rd place
719th place
424th place
3rd place
9th place
aventispharmaindia.com
- “Frisium Press Kit”. Aventis Pharma India. 2005년 3월 5일에 원본 문서에서 보존된 문서. 2006년 8월 2일에 확인함.
books.google.com
- Zirulia, Giuliano (2014). 《L'industria delle Medicine.》. EDRA LSWR. ISBN 9788821439049.
doi.org
dx.doi.org
- “Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group”. 《Epilepsia》 32 (3): 407–16. 1991. doi:10.1111/j.1528-1157.1991.tb04670.x. PMID 2044502. S2CID 24420211.
- Arya R, Giridharan N, Anand V, Garg SK (July 2018). “Clobazam monotherapy for focal or generalized seizures”. 《The Cochrane Database of Systematic Reviews》 7: CD009258. doi:10.1002/14651858.CD009258.pub3. PMC 6513499. PMID 29995989.
- Larrieu JL, Lagueny A, Ferrer X, Julien J (December 1986). “[Epilepsy with continuous discharges during slow-wave sleep. Treatment with clobazam]”. 《Revue d'Electroencephalographie et de Neurophysiologie Clinique》 (프랑스어) 16 (4): 383–94. doi:10.1016/S0370-4475(86)80028-4. PMID 3103177.
- Gastaut H, Tinuper P, Aguglia U, Lugaresi E (December 1984). “[Treatment of certain forms of status epilepticus by means of a single oral dose of clobazam]”. 《Revue d'Electroencephalographie et de Neurophysiologie Clinique》 14 (3): 203–6. doi:10.1016/S0370-4475(84)80005-2. PMID 6528075.
- Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K (July 2003). “Use of clobazam for the treatment of refractory complex partial seizures”. 《Seizure》 12 (5): 282–6. doi:10.1016/S1059-1311(02)00287-X. PMID 12810340.
- Monjanel-Mouterde S, Antoni M, Bun H, Botta-Frindlund D, Gauthier A, Durand A, Cano JP (June 1994). “Pharmacokinetics of a single oral dose of clobazam in patients with liver disease”. 《Pharmacology & Toxicology》 74 (6): 345–50. doi:10.1111/j.1600-0773.1994.tb01371.x. PMID 7937568.
- Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, 외. (November 2009). “Benzodiazepine dependence: focus on withdrawal syndrome”. 《Annales Pharmaceutiques Françaises》 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
- Thiébot MH, Le Bihan C, Soubrié P, Simon P (1985). “Benzodiazepines reduce the tolerance to reward delay in rats”. 《Psychopharmacology》 86 (1–2): 147–52. doi:10.1007/BF00431700. PMID 2862657. S2CID 30614502.
- Robertson MM (1986). “Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam”. 《Epilepsia》. 27 Suppl 1: S27–41. doi:10.1111/j.1528-1157.1986.tb05730.x. PMID 3527689. S2CID 23166797.
- MacKinnon GL, Parker WA (1982). “Benzodiazepine withdrawal syndrome: a literature review and evaluation”. 《The American Journal of Drug and Alcohol Abuse》 9 (1): 19–33. doi:10.3109/00952998209002608. PMID 6133446.
- Ralvenius WT, Acuña MA, Benke D, Matthey A, Daali Y, Rudolph U, 외. (October 2016). “The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia”. 《Neuropharmacology》 109: 366–375. doi:10.1016/j.neuropharm.2016.07.004. PMC 4981430. PMID 27392635.
- Nakajima H (August 2001). “[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]”. 《Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica》 118 (2): 117–22. doi:10.1254/fpj.118.117. PMID 11530681.
- Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L (February 1990). “Respiratory and sedative effects of clobazam and clonazepam in volunteers”. 《British Journal of Clinical Pharmacology》 29 (2): 169–77. doi:10.1111/j.1365-2125.1990.tb03616.x. PMC 1380080. PMID 2106335.
- McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, 외. (June 2000). “Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype”. 《Nature Neuroscience》 3 (6): 587–92. doi:10.1038/75761. PMID 10816315. S2CID 10340592.
- Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M (August 1996). “Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture”. 《Epilepsia》 37 (8): 728–35. doi:10.1111/j.1528-1157.1996.tb00643.x. PMID 8764810. S2CID 12628361.
- Tolbert D, Larsen F (January 2019). “A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam”. 《Journal of Clinical Pharmacology》 59 (1): 7–19. doi:10.1002/jcph.1313. PMC 6585772. PMID 30285275.
- Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A (December 2002). “Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam”. 《Therapeutic Drug Monitoring》 24 (6): 737–41. doi:10.1097/00007691-200212000-00009. PMID 12451290. S2CID 44444755.
- Giraud C, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G (November 2004). “In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19”. 《Drug Metabolism and Disposition》 32 (11): 1279–86. doi:10.1124/dmd.32.11.1279. PMID 15483195.
- Shorvon SD (March 2009). “Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009”. 《Epilepsia》. 50 Suppl 3: 93–130. doi:10.1111/j.1528-1167.2009.02042.x. PMID 19298435. S2CID 20445985.
- Hanks GW (1979). “Clobazam: pharmacological and therapeutic profile”. 《British Journal of Clinical Pharmacology》. 7 Suppl 1: 151S–155S. doi:10.1111/j.1365-2125.1979.tb04685.x. PMC 1429523. PMID 35198.
epilepsy.org.nz
- Epilepsy New Zealand (2000). “Antiepileptic Medication”. 2005년 3월 11일에 원본 문서에서 보존된 문서. 2005년 7월 11일에 확인함.
epilepsyontario.org
- “Clobazam”. 《Epilepsy Ontario》. 2020. 2020년 8월 21일에 확인함.
fda.gov
fda.gov
- “FDA expands Boxed Warning to improve safe use of benzodiazepine drug”. 《U.S. Food and Drug Administration (FDA)》. 2020년 9월 23일. 2020년 9월 23일에 확인함.
이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다. - FDA. December 3rd, 2013 FDA Drug Safety Podcast: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes
accessdata.fda.gov
- “Clobazam label” (PDF). December 2014.
inchem.org
- Fruchtengarten L Inchem - Clobazam. Created July 1997, Reviewed 1998.
lundbeckinc.com
- “FDA Approves ONFI™ (clobazam) for the Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Patients Two Years and Older” (보도 자료). Lundbeck. 2011년 10월 25일에 확인함.
medicines.org.uk
emc.medicines.org.uk
- sanofi-aventis (2002). “Frisium Tablets 10 mg, Summary of Product Characteristics from eMC”. 《electronic Medicines Compendium》. Medicines.org.uk. 2007년 12월 6일에 원본 문서에서 보존된 문서. 2005년 7월 11일에 확인함.
medscape.com
emedicine.medscape.com
- Ochoa JG (2005). “Antiepileptic Drugs: An Overview. GABA Receptor Agonists”. 《Drugs and Diseases》. Medccape. 2005년 7월 10일에 확인함.
nih.gov
ncbi.nlm.nih.gov
- Humayun MJ, Samanta D, Carson RP (2020). 〈Clobazam〉. 《StatPearls》. Treasure Island (FL): StatPearls Publishing. PMID 31082087.
- Freche C (April 1975). “[Study of an anxiolytic, clobazam, in otorhinolaryngology in psychosomatic pharyngeal manifestations]”. 《Semaine des Hopitaux. Therapeutique》 51 (4): 261–3. PMID 5777.
- “Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group”. 《Epilepsia》 32 (3): 407–16. 1991. doi:10.1111/j.1528-1157.1991.tb04670.x. PMID 2044502. S2CID 24420211.
- Arya R, Giridharan N, Anand V, Garg SK (July 2018). “Clobazam monotherapy for focal or generalized seizures”. 《The Cochrane Database of Systematic Reviews》 7: CD009258. doi:10.1002/14651858.CD009258.pub3. PMC 6513499. PMID 29995989.
- Isojärvi JI, Tokola RA (December 1998). “Benzodiazepines in the treatment of epilepsy in people with intellectual disability”. 《Journal of Intellectual Disability Research》. 42 Suppl 1 (Suppl 1): 80–92. PMID 10030438.
- Larrieu JL, Lagueny A, Ferrer X, Julien J (December 1986). “[Epilepsy with continuous discharges during slow-wave sleep. Treatment with clobazam]”. 《Revue d'Electroencephalographie et de Neurophysiologie Clinique》 (프랑스어) 16 (4): 383–94. doi:10.1016/S0370-4475(86)80028-4. PMID 3103177.
- Gastaut H, Tinuper P, Aguglia U, Lugaresi E (December 1984). “[Treatment of certain forms of status epilepticus by means of a single oral dose of clobazam]”. 《Revue d'Electroencephalographie et de Neurophysiologie Clinique》 14 (3): 203–6. doi:10.1016/S0370-4475(84)80005-2. PMID 6528075.
- Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K (July 2003). “Use of clobazam for the treatment of refractory complex partial seizures”. 《Seizure》 12 (5): 282–6. doi:10.1016/S1059-1311(02)00287-X. PMID 12810340.
- Monjanel-Mouterde S, Antoni M, Bun H, Botta-Frindlund D, Gauthier A, Durand A, Cano JP (June 1994). “Pharmacokinetics of a single oral dose of clobazam in patients with liver disease”. 《Pharmacology & Toxicology》 74 (6): 345–50. doi:10.1111/j.1600-0773.1994.tb01371.x. PMID 7937568.
- Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, 외. (November 2009). “Benzodiazepine dependence: focus on withdrawal syndrome”. 《Annales Pharmaceutiques Françaises》 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
- Thiébot MH, Le Bihan C, Soubrié P, Simon P (1985). “Benzodiazepines reduce the tolerance to reward delay in rats”. 《Psychopharmacology》 86 (1–2): 147–52. doi:10.1007/BF00431700. PMID 2862657. S2CID 30614502.
- WHO Review Group (1983). “Use and abuse of benzodiazepines”. 《Bulletin of the World Health Organization》 61 (4): 551–62. PMC 2536139. PMID 6605211.
- Loiseau P (1983). “[Benzodiazepines in the treatment of epilepsy]”. 《L'Encephale》 9 (4 Suppl 2): 287B–292B. PMID 6373234.
- Robertson MM (1986). “Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam”. 《Epilepsia》. 27 Suppl 1: S27–41. doi:10.1111/j.1528-1157.1986.tb05730.x. PMID 3527689. S2CID 23166797.
- MacKinnon GL, Parker WA (1982). “Benzodiazepine withdrawal syndrome: a literature review and evaluation”. 《The American Journal of Drug and Alcohol Abuse》 9 (1): 19–33. doi:10.3109/00952998209002608. PMID 6133446.
- Ralvenius WT, Acuña MA, Benke D, Matthey A, Daali Y, Rudolph U, 외. (October 2016). “The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia”. 《Neuropharmacology》 109: 366–375. doi:10.1016/j.neuropharm.2016.07.004. PMC 4981430. PMID 27392635.
- Nakajima H (August 2001). “[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]”. 《Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica》 118 (2): 117–22. doi:10.1254/fpj.118.117. PMID 11530681.
- Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L (February 1990). “Respiratory and sedative effects of clobazam and clonazepam in volunteers”. 《British Journal of Clinical Pharmacology》 29 (2): 169–77. doi:10.1111/j.1365-2125.1990.tb03616.x. PMC 1380080. PMID 2106335.
- McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, 외. (June 2000). “Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype”. 《Nature Neuroscience》 3 (6): 587–92. doi:10.1038/75761. PMID 10816315. S2CID 10340592.
- Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M (August 1996). “Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture”. 《Epilepsia》 37 (8): 728–35. doi:10.1111/j.1528-1157.1996.tb00643.x. PMID 8764810. S2CID 12628361.
- Tolbert D, Larsen F (January 2019). “A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam”. 《Journal of Clinical Pharmacology》 59 (1): 7–19. doi:10.1002/jcph.1313. PMC 6585772. PMID 30285275.
- Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A (December 2002). “Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam”. 《Therapeutic Drug Monitoring》 24 (6): 737–41. doi:10.1097/00007691-200212000-00009. PMID 12451290. S2CID 44444755.
- Giraud C, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G (November 2004). “In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19”. 《Drug Metabolism and Disposition》 32 (11): 1279–86. doi:10.1124/dmd.32.11.1279. PMID 15483195.
- Shorvon SD (March 2009). “Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009”. 《Epilepsia》. 50 Suppl 3: 93–130. doi:10.1111/j.1528-1167.2009.02042.x. PMID 19298435. S2CID 20445985.
- Hanks GW (1979). “Clobazam: pharmacological and therapeutic profile”. 《British Journal of Clinical Pharmacology》. 7 Suppl 1: 151S–155S. doi:10.1111/j.1365-2125.1979.tb04685.x. PMC 1429523. PMID 35198.
semanticscholar.org
api.semanticscholar.org
- “Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group”. 《Epilepsia》 32 (3): 407–16. 1991. doi:10.1111/j.1528-1157.1991.tb04670.x. PMID 2044502. S2CID 24420211.
- Thiébot MH, Le Bihan C, Soubrié P, Simon P (1985). “Benzodiazepines reduce the tolerance to reward delay in rats”. 《Psychopharmacology》 86 (1–2): 147–52. doi:10.1007/BF00431700. PMID 2862657. S2CID 30614502.
- Robertson MM (1986). “Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam”. 《Epilepsia》. 27 Suppl 1: S27–41. doi:10.1111/j.1528-1157.1986.tb05730.x. PMID 3527689. S2CID 23166797.
- McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, 외. (June 2000). “Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype”. 《Nature Neuroscience》 3 (6): 587–92. doi:10.1038/75761. PMID 10816315. S2CID 10340592.
- Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M (August 1996). “Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture”. 《Epilepsia》 37 (8): 728–35. doi:10.1111/j.1528-1157.1996.tb00643.x. PMID 8764810. S2CID 12628361.
- Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A (December 2002). “Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam”. 《Therapeutic Drug Monitoring》 24 (6): 737–41. doi:10.1097/00007691-200212000-00009. PMID 12451290. S2CID 44444755.
- Shorvon SD (March 2009). “Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009”. 《Epilepsia》. 50 Suppl 3: 93–130. doi:10.1111/j.1528-1167.2009.02042.x. PMID 19298435. S2CID 20445985.
t3db.ca
- “Clobazam (T3D4564)”. 《Toxin and Toxin Target Database (T3DB》.
web.archive.org
- sanofi-aventis (2002). “Frisium Tablets 10 mg, Summary of Product Characteristics from eMC”. 《electronic Medicines Compendium》. Medicines.org.uk. 2007년 12월 6일에 원본 문서에서 보존된 문서. 2005년 7월 11일에 확인함.
- “Frisium Press Kit”. Aventis Pharma India. 2005년 3월 5일에 원본 문서에서 보존된 문서. 2006년 8월 2일에 확인함.
- Epilepsy New Zealand (2000). “Antiepileptic Medication”. 2005년 3월 11일에 원본 문서에서 보존된 문서. 2005년 7월 11일에 확인함.